TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 MARKET ATTRACTIVENESS ANALYSIS 18 2 MARKET INTRODUCTION 2.1 DEFINITION 19 2.2 SCOPE OF THE STUDY 19 2.3 RESEARCH OBJECTIVE 19 2.4 MARKET STRUCTURE 19 2.5 ASSUMPTIONS & LIMITATIONS 20 3 RESEARCH METHODOLOGY 3.1 DATA MINING 21 3.2 SECONDARY RESEARCH 22 3.3 PRIMARY RESEARCH 23 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24 3.5 FORECASTING TECHNIQUES 25 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26 3.6.1 BOTTOM-UP APPROACH 27 3.6.2 TOP-DOWN APPROACH 27 3.7 DATA TRIANGULATION 28 3.8 VALIDATION 28 4 MARKET DYNAMICS 4.1 OVERVIEW 29 4.2 DRIVERS 30 4.2.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES 30 4.2.2 LAUNCH OF COMBINATION DRUGS 30 4.3 RESTRAINTS 31 4.3.1 COMPLEX REGULATORY REQUIREMENTS 31 4.4 OPPORTUNITIES 32 4.4.1 FOCUS ON EMERGING ECONOMIES AND BOOSTING R&D 32 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 33 5.1.1 R&D AND DESIGNING 34 5.1.2 MANUFACTURING 34 5.1.3 DISTRIBUTION & SALES 34 5.1.4 POST-SALES SERVICES 34 5.2 PORTER’S FIVE FORCES MODEL 35 5.2.1 BARGAINING POWER OF SUPPLIERS 36 5.2.2 BARGAINING POWER OF BUYERS 36 5.2.3 THREAT OF NEW ENTRANTS 36 5.2.4 THREAT OF SUBSTITUTES 36 5.2.5 RIVALRY 36 5.3 IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION MARKET 37 5.3.1 OVERVIEW 37 5.3.2 IMPACT ON SUPPLY CHAIN 37 5.3.3 IMPACT ON PRODUCTION 38 6 GLOBAL URINARY TRACT INFECTION MARKET BY DRUG CLASS 6.1 OVERVIEW 40 6.2 QUINOLONES 42 6.3 Β-LACTAM & CEPHALOSPORINS 43 6.4 AMINOGLYCOSIDES 44 6.5 PENICILLIN 44 6.6 AZOLES 45 7 GLOBAL URINARY TRACT INFECTION MARKET BY APPLICATION 7.1 OVERVIEW 46 7.2 URETHRITIS 47 7.3 CYSTITIS 48 7.4 PYELONEPHRITIS 48 8 GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN 8.1 OVERVIEW 49 8.2 ESCHERICHIA COLI 50 8.3 STAPHYLOCOCCUS SAPROPHYTICUS 51 8.4 KLEBSIELLA PNEUMONIAE 51 8.5 PROTEUS MIRABILIS 52 8.6 ENTEROCOCCUS FAECALIS 52 9 GLOBAL URINARY TRACT INFECTION MARKET BY END USER 9.1 OVERVIEW 53 9.2 HOSPITALS 54 9.3 CLINICS 54 9.4 SELF-ADMINISTERED 55 10 GLOBAL URINARY TRACT INFECTION MARKET BY REGION 10.1 OVERVIEW 56 10.2 AMERICAS 58 10.2.1 NORTH AMERICA 61 10.2.1.1 US 64 10.2.1.2 CANADA 67 10.2.2 LATIN AMERICA 70 10.3 EUROPE 73 10.3.1 WESTERN EUROPE 76 10.3.1.1 GERMANY 80 10.3.1.2 FRANCE 83 10.3.1.3 UK 86 10.3.1.4 ITALY 89 10.3.1.5 SPAIN 92 10.3.1.6 REST OF WESTERN EUROPE 95 10.3.2 EASTERN EUROPE 98 10.4 ASIA-PACIFIC 101 10.4.1 CHINA 105 10.4.2 INDIA 108 10.4.3 JAPAN 111 10.4.4 AUSTRALIA 114 10.4.5 SOUTH KOREA 117 10.4.6 REST OF ASIA-PACIFIC 120 10.5 MIDDLE EAST & AFRICA 123 10.5.1 MIDDLE EAST 126 10.5.2 AFRICA 129 11 COMPETITIVE LANDSCAPE 11.1 OVERVIEW 132 11.2 COMPETITIVE BENCHMARKING 133 11.3 GLOBAL URINARY TRACT INFECTION MARKET: COMPANY RANKING, 2019 134 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES 134 11.4.1 PRODUCT APPROVALS AND LAUNCHES 134 11.4.2 ACQUISITIONS 134 11.5 FINANCIAL MATRIX 135 12 COMPANY PROFILES 12.1 PFIZER INC. 136 12.1.1 COMPANY OVERVIEW 136 12.1.2 FINANCIAL OVERVIEW 137 12.1.3 PRODUCTS/SERVICES OFFERED 138 12.1.4 KEY DEVELOPMENTS 138 12.1.5 SWOT ANALYSIS 138 12.1.6 KEY STRATEGIES 139 12.2 NOVO NORDISK A/S 140 12.2.1 COMPANY OVERVIEW 140 12.2.2 FINANCIAL OVERVIEW 140 12.2.3 PRODUCTS/SERVICES OFFERED 141 12.2.4 KEY DEVELOPMENTS 141 12.2.5 SWOT ANALYSIS 141 12.2.6 KEY STRATEGIES 141 12.3 NOVARTIS AG 142 12.3.1 COMPANY OVERVIEW 142 12.3.2 FINANCIAL OVERVIEW 142 12.3.3 PRODUCTS/SERVICES OFFERED 143 12.3.4 KEY DEVELOPMENTS 143 12.3.5 SWOT ANALYSIS 143 12.3.6 KEY STRATEGIES 144 12.4 MERCK & CO., INC. 145 12.4.1 COMPANY OVERVIEW 145 12.4.2 FINANCIAL OVERVIEW 145 12.4.3 PRODUCTS/SERVICES OFFERED 146 12.4.4 KEY DEVELOPMENTS 146 12.4.5 SWOT ANALYSIS 146 12.4.6 KEY STRATEGIES 146 12.5 ELI LILY AND COMPANY 147 12.5.1 COMPANY OVERVIEW 147 12.5.2 FINANCIAL OVERVIEW 147 12.5.3 PRODUCTS/SERVICES OFFERED 148 12.5.4 KEY DEVELOPMENTS 148 12.5.5 SWOT ANALYSIS 148 12.5.6 KEY STRATEGIES 148 12.6 ALLERGAN 149 12.6.1 COMPANY OVERVIEW 149 12.6.2 FINANCIAL OVERVIEW 149 12.6.3 PRODUCTS/SERVICES OFFERED 150 12.6.4 KEY DEVELOPMENTS 150 12.6.5 SWOT ANALYSIS 150 12.6.6 KEY STRATEGIES 150 12.7 CIPLA INC. 151 12.7.1 COMPANY OVERVIEW 151 12.7.2 FINANCIAL OVERVIEW 151 12.7.3 PRODUCTS/SERVICES OFFERED 151 12.7.4 KEY DEVELOPMENTS 151 12.7.5 SWOT ANALYSIS 152 12.7.6 KEY STRATEGIES 152 12.8 TEVA PHARMACEUTICALS 153 12.8.1 COMPANY OVERVIEW 153 12.8.2 FINANCIAL OVERVIEW 153 12.8.3 PRODUCTS/SERVICES OFFERED 154 12.8.4 KEY DEVELOPMENTS 154 12.8.5 SWOT ANALYSIS 154 12.8.6 KEY STRATEGIES 155 12.9 GLAXOSMITHKLINE PLC 156 12.9.1 COMPANY OVERVIEW 156 12.9.2 FINANCIAL OVERVIEW 156 12.9.3 PRODUCTS/SERVICES OFFERED 157 12.9.4 KEY DEVELOPMENTS 157 12.9.5 SWOT ANALYSIS 157 12.9.6 KEY STRATEGIES 157 12.10 BAYER AG 158 12.10.1 COMPANY OVERVIEW 158 12.10.2 COMPANY VALUE 158 12.10.3 FINANCIAL OVERVIEW 159 12.10.4 PRODUCTS/SERVICES OFFERED 159 12.10.5 KEY DEVELOPMENTS 159 12.10.6 SWOT ANALYSIS 160 12.10.7 KEY STRATEGIES 160 13 APPENDIX 13.1 REFERENCES 161 13.2 RELATED REPORTS 161

LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 20 TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23 TABLE 3 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 41 TABLE 4 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY REGION, 2017-2027 (USD MILLION) 42 TABLE 5 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 42 TABLE 6 GLOBAL URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY REGION, 2017-2027 (USD MILLION) 43 TABLE 7 GLOBAL URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 43 TABLE 8 GLOBAL URINARY TRACT INFECTION MARKET, FOR AMINOGLYCOSIDES, BY REGION, 2017-2027 (USD MILLION) 44 TABLE 9 GLOBAL URINARY TRACT INFECTION MARKET, FOR PENICILLIN, BY REGION, 2017-2027 (USD MILLION) 44 TABLE 10 GLOBAL URINARY TRACT INFECTION MARKET, FOR AZOLES, BY REGION, 2017-2027 (USD MILLION) 45 TABLE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 47 TABLE 12 GLOBAL URINARY TRACT INFECTION MARKET, FOR URETHRITIS, BY REGION, 2017-2027 (USD MILLION) 47 TABLE 13 GLOBAL URINARY TRACT INFECTION MARKET, FOR CYSTITIS, BY REGION, 2017-2027 (USD MILLION) 48 TABLE 14 GLOBAL URINARY TRACT INFECTION MARKET, FOR PYELONEPHRITIS, BY REGION, 2017-2027 (USD MILLION) 48 TABLE 15 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 50 TABLE 16 GLOBAL URINARY TRACT INFECTION MARKET, FOR ESCHERICHIA COLI, BY REGION, 2017-2027 (USD MILLION) 50 TABLE 17 GLOBAL URINARY TRACT INFECTION MARKET, FOR STAPHYLOCOCCUS SAPROPHYTICUS, BY REGION, 2017-2027 (USD MILLION) 51 TABLE 18 GLOBAL URINARY TRACT INFECTION MARKET, FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2017-2027 (USD MILLION) 51 TABLE 19 GLOBAL URINARY TRACT INFECTION MARKET, FOR PROTEUS MIRABILIS, BY REGION, 2017-2027 (USD MILLION) 52 TABLE 20 GLOBAL URINARY TRACT INFECTION MARKET, FOR ENTEROCOCCUS FAECALIS, BY REGION, 2017-2027 (USD MILLION) 52 TABLE 21 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 54 TABLE 22 GLOBAL URINARY TRACT INFECTION MARKET, FOR HOSPITALS, BY REGION, 2017-2027 (USD MILLION) 54 TABLE 23 GLOBAL URINARY TRACT INFECTION MARKET, FOR CLINICS, BY REGION, 2017-2027 (USD MILLION) 54 TABLE 24 GLOBAL URINARY TRACT INFECTION MARKET, FOR SELF-ADMINISTERED, BY REGION, 2017-2027 (USD MILLION) 55 TABLE 25 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 57 TABLE 26 AMERICAS: URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 58 TABLE 27 AMERICAS: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 58 TABLE 28 AMERICAS: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 59 TABLE 29 AMERICAS: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 59 TABLE 30 AMERICAS: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 60 TABLE 31 AMERICAS: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 60 TABLE 32 AMERICAS: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 60 TABLE 33 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 61 TABLE 34 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 61 TABLE 35 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 62 TABLE 36 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 62 TABLE 37 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 63 TABLE 38 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 63 TABLE 39 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 63 TABLE 40 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 64 TABLE 41 US: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 64 TABLE 42 US: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 65 TABLE 43 US: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 65 TABLE 44 US: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 66 TABLE 45 US: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 66 TABLE 46 CANADA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 67 TABLE 47 CANADA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 67 TABLE 48 CANADA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 68 TABLE 49 CANADA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 68 TABLE 50 CANADA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 69 TABLE 51 CANADA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 69 TABLE 52 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 70 TABLE 53 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 70 TABLE 54 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 71 TABLE 55 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 72 TABLE 56 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 72 TABLE 57 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 72 TABLE 58 EUROPE: URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 73 TABLE 59 EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 73 TABLE 60 EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 74 TABLE 61 EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 74 TABLE 62 EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 75 TABLE 63 EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 75 TABLE 64 EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 75 TABLE 65 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 76 TABLE 66 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 77 TABLE 67 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 77 TABLE 68 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 78 TABLE 69 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 78 TABLE 70 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 79 TABLE 71 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 79 TABLE 72 GERMANY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 80 TABLE 73 GERMANY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 80 TABLE 74 GERMANY: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 81 TABLE 75 GERMANY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 81 TABLE 76 GERMANY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 82 TABLE 77 GERMANY: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 82 TABLE 78 FRANCE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 83 TABLE 79 FRANCE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 83 TABLE 80 FRANCE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 84 TABLE 81 FRANCE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 84 TABLE 82 FRANCE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 85 TABLE 83 FRANCE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 85 TABLE 84 UK: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 86 TABLE 85 UK: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 86 TABLE 86 UK: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 87 TABLE 87 UK: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 87 TABLE 88 UK: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 88 TABLE 89 UK: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 88 TABLE 90 ITALY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 89 TABLE 91 ITALY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 89 TABLE 92 ITALY: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 90 TABLE 93 ITALY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 90 TABLE 94 ITALY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 91 TABLE 95 ITALY: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 91 TABLE 96 SPAIN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 92 TABLE 97 SPAIN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 92 TABLE 98 SPAIN: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 93 TABLE 99 SPAIN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 93 TABLE 100 SPAIN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 94 TABLE 101 SPAIN: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 94 TABLE 102 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 95 TABLE 103 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 95 TABLE 104 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 96 TABLE 105 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 96 TABLE 106 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 97 TABLE 107 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 97 TABLE 108 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 98 TABLE 109 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 98 TABLE 110 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 99 TABLE 111 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 99 TABLE 112 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 100 TABLE 113 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 100 TABLE 114 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 101 TABLE 115 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 102 TABLE 116 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 102 TABLE 117 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 103 TABLE 118 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 103 TABLE 119 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 104 TABLE 120 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 104 TABLE 121 CHINA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 105 TABLE 122 CHINA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 105 TABLE 123 CHINA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 106 TABLE 124 CHINA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 106 TABLE 125 CHINA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 107 TABLE 126 CHINA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 107 TABLE 127 INDIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 108 TABLE 128 INDIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 108 TABLE 129 INDIA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 109 TABLE 130 INDIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 109 TABLE 131 INDIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 110 TABLE 132 INDIA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 110 TABLE 133 JAPAN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 111 TABLE 134 JAPAN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 111 TABLE 135 JAPAN: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 112 TABLE 136 JAPAN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 112 TABLE 137 JAPAN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 113 TABLE 138 JAPAN: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 113 TABLE 139 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 114 TABLE 140 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 114 TABLE 141 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 115 TABLE 142 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 115 TABLE 143 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 116 TABLE 144 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 116 TABLE 145 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 117 TABLE 146 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 117 TABLE 147 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 118 TABLE 148 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 118 TABLE 149 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 119 TABLE 150 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 119 TABLE 151 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 120 TABLE 152 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 120 TABLE 153 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 121 TABLE 154 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 121 TABLE 155 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 122 TABLE 156 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 122 TABLE 157 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 123 TABLE 158 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 123 TABLE 159 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 124 TABLE 160 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 124 TABLE 161 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 125 TABLE 162 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 125 TABLE 163 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 125 TABLE 164 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 126 TABLE 165 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 126 TABLE 166 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 127 TABLE 167 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 127 TABLE 168 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 128 TABLE 169 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 128 TABLE 170 AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 129 TABLE 171 AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 129 TABLE 172 AFRICA: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 130 TABLE 173 AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 130 TABLE 174 AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 131 TABLE 175 AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 131 TABLE 176 MAJOR MANUFACTURERS RANKING, 2019 134 TABLE 177 PRODUCT APPROVALS AND LAUNCHES 134 TABLE 178 ACQUISITIONS 134 TABLE 179 PFIZER INC.: PRODUCTS/SERVICES OFFERED 138 TABLE 180 NOVO NORDISK A/S: PRODUCTS/SERVICES OFFERED 141 TABLE 181 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 143 TABLE 182 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 146 TABLE 183 ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED 148 TABLE 184 ALLERGAN: PRODUCTS/SERVICES OFFERED 150 TABLE 185 CIPLA INC.: PRODUCTS/SERVICES OFFERED 151 TABLE 186 CIPLA INC.: KEY DEVELOPMENTS 151 TABLE 187 TEVA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154 TABLE 188 TEVA PHARMACEUTICALS: KEY DEVELOPMENTS 154 TABLE 189 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 157 TABLE 190 BAYER AG: COMPANY VALUE 158 TABLE 191 BAYER AG.: PRODUCTS/SERVICES OFFERED 159

Pfizer Inc., Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc., Eli Lily and Company, Allergan, Cipla Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Bayer AG